{"id":"https://openalex.org/G8554189727","display_name":"The CXCR3 Chemokine System in Cancer Immunotherapy","description":"PROJECT NARRATIVE Immune checkpoint blockade therapy for cancer can result in durable clinical responses; however, it is only effective in a fraction of patients. Improving the efficacy of cancer immunotherapy will require a better understanding of the molecules that control the complex interactions of immune cells in the tumor microenvironment required for effective therapy, and their regulation by checkpoint blockade. This project will study how the chemokine receptor CXCR3 and its ligands, CXCL9 and CXCL10, contribute in critical ways to efficacy of checkpoint blockade immunotherapy, and how to use this knowledge to harness the potential of this approach to benefit more cancer patients.","funder_award_id":"R01CA204028","funder":{"id":"https://openalex.org/F4320337351","display_name":"National Cancer Institute","doi":"https://doi.org/10.13039/100000054"},"funded_outputs":["https://openalex.org/W33838745","https://openalex.org/W2726768474","https://openalex.org/W2754366826","https://openalex.org/W2801287725","https://openalex.org/W2801762127","https://openalex.org/W2940124943","https://openalex.org/W2945224722","https://openalex.org/W2996756464","https://openalex.org/W3029514565","https://openalex.org/W3039699388","https://openalex.org/W3156068899","https://openalex.org/W3188702988","https://openalex.org/W3189614948","https://openalex.org/W3215848439","https://openalex.org/W3216331379"],"funded_outputs_count":15,"parent_awards":[],"sub_awards":[],"sub_awards_count":0,"amount":null,"currency":"USD","amount_usd":null,"amount_usd_basis":null,"recipients":[],"recipient_countries":[],"recipient_regions":[],"research_scope":{"is_research":true,"basis":"funder_default","tier":1},"funding_type":"research","funder_scheme":"R01","start_date":"2016-12-01","end_date":"2023-05-31","start_year":2016,"end_year":2023,"landing_page_url":"https://reporter.nih.gov/project-details/9606440","doi":null,"provenance":"nih_exporter","lead_investigator":{"given_name":"ANDREW D","family_name":"LUSTER","orcid":null,"role_start":null,"affiliation":{"name":"MASSACHUSETTS GENERAL HOSPITAL","country":"UNITED STATES","ids":null},"author":{"id":"https://openalex.org/A5055995920","display_name":"Andrew David Luster","orcid":"https://orcid.org/0000-0001-9679-7912"},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}]},"co_lead_investigator":null,"investigators":null,"works_api_url":"https://api.openalex.org/works?filter=awards.id:G8554189727","primary_topic":{"id":"https://openalex.org/T11532","display_name":"Chemokine receptors and signaling","score":0.9512,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11532","display_name":"Chemokine receptors and signaling","score":0.9512,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.0471,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10031","display_name":"T-cell and B-cell Immunology","score":0.0001,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/cxcr3","display_name":"CXCR3","score":0.992},{"id":"https://openalex.org/keywords/cxcl9","display_name":"CXCL9","score":0.928},{"id":"https://openalex.org/keywords/cxcl10","display_name":"CXCL10","score":1.0},{"id":"https://openalex.org/keywords/chemokine-receptors","display_name":"chemokine receptors","score":0.778},{"id":"https://openalex.org/keywords/immune-checkpoint-blockade","display_name":"immune checkpoint blockade","score":0.956},{"id":"https://openalex.org/keywords/cancer-immunotherapy","display_name":"cancer immunotherapy","score":0.994},{"id":"https://openalex.org/keywords/tumor-microenvironment","display_name":"tumor microenvironment","score":0.981},{"id":"https://openalex.org/keywords/immune-cell-interactions","display_name":"immune cell interactions","score":0.622},{"id":"https://openalex.org/keywords/treatment-response","display_name":"treatment response","score":0.431}],"sustainable_development_goals":[{"score":0.9763,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"institution_awarded":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"updated_date":"2026-11-13T03:01:57.000Z","created_date":"2026-10-09T19:56:01.000Z"}
